Sanofi - Aventis Groupe: Press Release: Dupixent (dupilumab)

Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program

Related Keywords

Japan , Paris , France General , France , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Georged Yancopoulos , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Naimish Patel , Priya Nanduri , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Drug Administration , Dupilumab Development Program , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , European Union , European Medicines Agency , Head Of Global Development , Euronext , Priority Review , Global Development , Chief Scientific Officer , Dupixent Prurigo Nodularis , Worst Itch Numeric Rating Scale , Global Assessment , Regeneron Genetics , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Sanofi , Eventis , Roupe , Dress , Release , Dupixent , Dupilumab , Approved , First , Only , Treatment , Syndicated , Prurigo , Nodularis ,